211 related articles for article (PubMed ID: 26916019)
1. Alterations within the Osteo-Hematopoietic Niche in MDS and their Therapeutic Implications.
Mies A; Bulycheva E; Rogulj IM; Hofbauer LC; Platzbecker U
Curr Pharm Des; 2016; 22(16):2323-32. PubMed ID: 26916019
[TBL] [Abstract][Full Text] [Related]
2. Effects of rigosertib on the osteo-hematopoietic niche in myelodysplastic syndromes.
Balaian E; Weidner H; Wobus M; Baschant U; Jacobi A; Mies A; Bornhäuser M; Guck J; Hofbauer LC; Rauner M; Platzbecker U
Ann Hematol; 2019 Sep; 98(9):2063-2072. PubMed ID: 31312928
[TBL] [Abstract][Full Text] [Related]
3. Bone marrow niche in the myelodysplastic syndromes.
Cogle CR; Saki N; Khodadi E; Li J; Shahjahani M; Azizidoost S
Leuk Res; 2015 Oct; 39(10):1020-7. PubMed ID: 26276090
[TBL] [Abstract][Full Text] [Related]
4. Mesenchymal Stem and Progenitor Cells in Normal and Dysplastic Hematopoiesis-Masters of Survival and Clonality?
Pleyer L; Valent P; Greil R
Int J Mol Sci; 2016 Jun; 17(7):. PubMed ID: 27355944
[TBL] [Abstract][Full Text] [Related]
5. The microenvironment in myelodysplastic syndromes: Niche-mediated disease initiation and progression.
Li AJ; Calvi LM
Exp Hematol; 2017 Nov; 55():3-18. PubMed ID: 28826860
[TBL] [Abstract][Full Text] [Related]
6. Mesenchymal Stem Cells in Aplastic Anemia and Myelodysplastic Syndromes: The "Seed and Soil" Crosstalk.
Fattizzo B; Giannotta JA; Barcellini W
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32751628
[TBL] [Abstract][Full Text] [Related]
7. Physician Education: Myelodysplastic Syndrome.
Yoshida Y
Oncologist; 1996; 1(4):284-287. PubMed ID: 10388004
[TBL] [Abstract][Full Text] [Related]
8. Myelodysplastic Syndromes and Metabolism.
Balaian E; Wobus M; Bornhäuser M; Chavakis T; Sockel K
Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681910
[TBL] [Abstract][Full Text] [Related]
9. Hematopathological alterations of major tumor suppressor cascade, vital cell cycle inhibitors and hematopoietic niche components in experimental myelodysplasia.
Chatterjee R; Gupta S; Law S
Chem Biol Interact; 2017 Aug; 273():1-10. PubMed ID: 28549617
[TBL] [Abstract][Full Text] [Related]
10. Coexistence of aberrant hematopoietic and stromal elements in myelodysplastic syndromes.
Abbas S; Kini A; Srivastava VM; M MT; Nair SC; Abraham A; Mathews V; George B; Kumar S; Venkatraman A; Srivastava A
Blood Cells Mol Dis; 2017 Jul; 66():37-46. PubMed ID: 28822917
[TBL] [Abstract][Full Text] [Related]
11. Germline mutations in the bone marrow microenvironment and dysregulated hematopoiesis.
Miller LH; Qu CK; Pauly M
Exp Hematol; 2018 Oct; 66():17-26. PubMed ID: 30076950
[TBL] [Abstract][Full Text] [Related]
12. Myelodysplastic cells in patients reprogram mesenchymal stromal cells to establish a transplantable stem cell niche disease unit.
Medyouf H; Mossner M; Jann JC; Nolte F; Raffel S; Herrmann C; Lier A; Eisen C; Nowak V; Zens B; Müdder K; Klein C; Obländer J; Fey S; Vogler J; Fabarius A; Riedl E; Roehl H; Kohlmann A; Staller M; Haferlach C; Müller N; John T; Platzbecker U; Metzgeroth G; Hofmann WK; Trumpp A; Nowak D
Cell Stem Cell; 2014 Jun; 14(6):824-37. PubMed ID: 24704494
[TBL] [Abstract][Full Text] [Related]
13. The bone-marrow niche in MDS and MGUS: implications for AML and MM.
Ghobrial IM; Detappe A; Anderson KC; Steensma DP
Nat Rev Clin Oncol; 2018 Apr; 15(4):219-233. PubMed ID: 29311715
[TBL] [Abstract][Full Text] [Related]
14. Regulation of hematopoiesis by activators and inhibitors of Wnt signaling from the niche.
Schreck C; Bock F; Grziwok S; Oostendorp RA; Istvánffy R
Ann N Y Acad Sci; 2014 Mar; 1310():32-43. PubMed ID: 24611828
[TBL] [Abstract][Full Text] [Related]
15. Biology of the bone marrow microenvironment and myelodysplastic syndromes.
Rankin EB; Narla A; Park JK; Lin S; Sakamoto KM
Mol Genet Metab; 2015; 116(1-2):24-8. PubMed ID: 26210353
[TBL] [Abstract][Full Text] [Related]
16. What is the role of the microenvironment in MDS?
Calvi LM; Li AJ; Becker MW
Best Pract Res Clin Haematol; 2019 Dec; 32(4):101113. PubMed ID: 31779976
[TBL] [Abstract][Full Text] [Related]
17. Feedback signals in myelodysplastic syndromes: increased self-renewal of the malignant clone suppresses normal hematopoiesis.
Walenda T; Stiehl T; Braun H; Fröbel J; Ho AD; Schroeder T; Goecke TW; Rath B; Germing U; Marciniak-Czochra A; Wagner W
PLoS Comput Biol; 2014 Apr; 10(4):e1003599. PubMed ID: 24763223
[TBL] [Abstract][Full Text] [Related]
18. [Senescent Mesenchymal Stem Cells Contribute to Progression of Myelodysplastic Syndromes-Review].
Pang YB; Li WW; Luo JM; Ji J; DU X
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2018 Jun; 26(3):942-946. PubMed ID: 29950248
[TBL] [Abstract][Full Text] [Related]
19. Uncovering perturbations in human hematopoiesis associated with healthy aging and myeloid malignancies at single-cell resolution.
Ainciburu M; Ezponda T; Berastegui N; Alfonso-Pierola A; Vilas-Zornoza A; San Martin-Uriz P; Alignani D; Lamo-Espinosa J; San-Julian M; Jiménez-Solas T; Lopez F; Muntion S; Sanchez-Guijo F; Molero A; Montoro J; Serrano G; Diaz-Mazkiaran A; Lasaga M; Gomez-Cabrero D; Diez-Campelo M; Valcarcel D; Hernaez M; Romero JP; Prosper F
Elife; 2023 Jan; 12():. PubMed ID: 36629404
[TBL] [Abstract][Full Text] [Related]
20. Osteogenic niche in the regulation of normal hematopoiesis and leukemogenesis.
Le PM; Andreeff M; Battula VL
Haematologica; 2018 Dec; 103(12):1945-1955. PubMed ID: 30337364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
